Live Breaking News & Updates on Myt Platform|Page 1

Stay updated with breaking news from Myt platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

SAN FRANCISCO and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver ....

France General , Camille Landis , Max Delbr , Elisa Kieback , Therapeutics Inc , Globe Newswire Therapeutics Inc , Life Sciences , International Society For Cell Gene Therapy , International Society , Gene Therapy , Annual Meeting , Chief Technology Officer , Myt Platform , Molecular Medicine , Andera Partners , Business Officer , Chief Financial ,

Investegate |T-knife Therapeutics Announcements | T-knife Therapeutics: T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer ....

United States , San Francisco , Max Delbr , Behzad Kharabi , Thomasm Soloway , Camille Landis , Behzad Kharabi Masouleh , University Of California , University Hospital Of Aachen , Therapeutics Inc , Globe Newswire Therapeutics Inc , Janssen Pharmaceuticals , Life Sciences , University Of Muenster , Memorial Sloan Kettering Cancer Center , T Knife Therapeutics Announces , Chief Medical , Chief Executive Officer , Eugen Leo , University Hospital , Ernst Jung Award , Myt Platform , Molecular Medicine , Andera Partners , Business Officer , Chief Financial ,

T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer

SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver ....

United States , San Francisco , Max Delbr , Thomasm Soloway , Schwierige Zeiten , Camille Landis , Behzad Kharabi Masouleh , University Of California , University Hospital Of Aachen , Therapeutics Inc , Globe Newswire Therapeutics Inc , Janssen Pharmaceuticals , Life Sciences , University Of Muenster , Memorial Sloan Kettering Cancer Center , Chief Medical , Chief Executive Officer , Eugen Leo , University Hospital , Ernst Jung Award , Myt Platform , Molecular Medicine , Andera Partners , Business Officer , Chief Financial ,

Investegate |T-knife Therapeutics Announcements | T-knife Therapeutics: T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial ....

Max Delbr , Thomasm Soloway , Camille Landis , Therapeutics Inc , Globe Newswire Therapeutics Inc , T Knife Therapeutics Announces Dosing , First Patient , Melanoma Associated Antigen Gene A , Myt Platform , Eugen Leo , Chief Medical Officer , Chief Executive Officer , T Knife Myt , Molecular Medicine , Business Officer , Chief Financial , Investegate Announcements , Investegate Company Announcements , T Knife Therapeutics , Lobenewswire And Globenewswire ,

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors TK-8001 targets a MAGE-A1 epitope ....

Max Delbr , Kostenloser Wertpapierhandel , Thomasm Soloway , Camille Landis , Therapeutics Inc , Globe Newswire Therapeutics Inc , Melanoma Associated Antigen Gene A , Myt Platform , Eugen Leo , Chief Medical Officer , Chief Executive Officer , T Knife Myt , Molecular Medicine , Business Officer , Chief Financial ,